Establishment Registration versus Device Listing under 21 CFR Part 807

1. Key takeaways

Establishment Registration records the location and the activities conducted at that location; Device Listing records every device manufactured or processed at that location. The two are bound together under 21 CFR Part 807: registration is the carrier of the listing, and the listing extends the content of the registration, and both must complete annual renewal between October 1 and December 31 each year. Reading them as a pair, rather than as two unrelated filings, is what keeps the compliance structure coherent: a registered establishment with no listings is an empty shell, and a listing that references no valid registration cannot stand. Companies operating multiple sites or multiple product lines should therefore maintain the registration and listing records as one integrated ledger in which every product can be traced to a site and every site to its products without gaps.

• Initial registration and listing are due within 30 days after commencing the relevant activity, with both submitted together under 21 CFR 807.22(a).
• Annual renewal runs from October 1 through December 31 under 21 CFR 807.22(b)(1)(3), and must be completed even when nothing has changed.
• Changes to registration information must be reported within 30 days under 21 CFR 807.22(b)(2).
• Missing the deadlines moves the establishment into a failed to register or failed to list status, so the site is no longer considered active.
• Nine categories of firms must register, including contract manufacturers, contract sterilizers, repackers, relabelers, and specification developers.

2. Legal basis

The authorities below carry the timing rules, the information requirements, and the consequences of non-compliance for registration and listing. The 2012 and 2020 amendments are noted where they fixed the current wording, so that readers tracing historical citations can anchor each rule to the Federal Register document that produced it.

3. Expert insights

Insight one: the scope of registration subjects is far wider than the word manufacturer suggests.

FDA’s official pages enumerate the firms that must register and list as including manufacturers, contract manufacturers, contract sterilizers, repackers and relabelers, specification developers, reprocessors of single-use devices, remanufacturers, manufacturers of accessories and components sold directly to end users, and manufacturers in the United States of devices exported only. That makes nine categories of subjects, and contract manufacturers and sterilizers must register separately in their own right. Brands routinely assume that their own registration covers the facilities they pay to produce or sterilize their goods; it does not. Each such facility is an independent registration subject with its own numbers, its own renewal obligation, and its own exposure if the annual window is missed, so the whole supply chain must be swept during scoping, not just the company’s own premises.

Insight two: initial registration is triggered by a 30-day clock, and its content is submitted together with the listing.

Under 21 CFR 807.22(a), the owner or operator of an establishment that has not previously engaged in the relevant activity must register within 30 days of entering that activity, and at the same time submit the device listing information. Registration and listing are two parts of a single action, not two separate projects to be scheduled apart. Treating them together avoids the awkward intermediate state in which a site exists in FDA’s systems with no products attached to it, which raises questions during inspection and can complicate customs entries until the listing records catch up with the registration.

Insight three: missing a deadline does not bring a fine; it brings status failure and a border block.

Under 21 CFR 807.22(c), failure to submit on time places the establishment in a failed to register or failed to list status, and the establishment is no longer considered active, with its registration and listing information potentially absent from the FDA website. At the border, that condition feeds directly into detention without physical examination under Import Alert 99-34. The commercial consequence is that goods already shipped or in transit cannot be released, which is generally far more expensive than any administrative penalty would have been. The annual window therefore deserves a hard calendar control with an internal deadline ahead of December 31, and the confirmation step must be performed even in years when nothing has changed, because silence is what creates the failed status.

4. Practical recommendations

• Manage the structure with a site ledger: one record per establishment, containing the activity type, the registration number, and the list of listing numbers attached to it.
• Register contract manufacturers, sterilizers, and specification developers separately, and never fold them into the brand owner’s own registration.
• Start the annual renewal on October 1 each year and finish before December 31; complete the confirmation even when no information has changed.
• Update establishment information, including name, address, and Official Correspondent, within 30 days of any change.

5. Verification checklist

• □ All establishments requiring registration have been enumerated, including contract manufacturers and sterilizers.
• □ The activity type recorded for each establishment has been confirmed as correct.
• □ Initial registration was completed within 30 days of entering the relevant activity.
• □ A calendar for the October 1 through December 31 annual renewal has been set up.
• □ An owner for the 30-day update of changed information has been designated.
• □ An Official Correspondent has been designated, whose email can receive FDA number notifications.

Regulatory information verified as of October 28, 2026.

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, US Agent and local testing support for the United States market. Our team manages FDA establishment registration and listing, 510(k)/De Novo/PMA submissions, and supports post-market reporting obligations. Business enquiries: info@grzanglobal.com